Davide Rossi
Has grant
Associate Professor of Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Oncogenic perturbations of the non-coding regulatory genome in classic Hodgkin lymphoma
Open Date: 2024-05-01
Close Date: 2028-04-01
Grant: Close
Dynamic risk profiling for the identification of patients with high-risk diffuse large B-cell lymphoma
Open Date: 2024-04-01
Close Date: 2026-03-01
Grant: Close
Finanziamento Ricercatori Senior
Open Date: 2024-01-01
Close Date: 2024-12-01
Grant: Open
Multilayer taxonomy of nodal marginal zone lymphoma
Open Date: 2024-01-01
Close Date: 2026-12-31
Grant: Close
Uncovering the pathophysiology and vulnerability of minimal residual disease persisting under ventoclax in patients with chronic lymphocytic leukemia
Open Date: 2023-05-01
Close Date: 2025-04-01
Articles (89)
Cyclin-dependent kinase 9 (CDK9) drives transcriptional elongation and supports the expression of short-lived oncogenic and anti-apoptotic proteins such as MYC and MCL1. PRT2527 is a potent, selective CDK9 inhibitor currently in early clinical development. We evaluated its preclinical activity in marginal zone lymphoma (MZL) models, including cell lines with acquired resistance to BTK, PI3K, and BCL2 inhibitors. Short exposure (4 hours) to PRT2527 produced nanomolar cytotoxicity across all tested MZL cell lines, with efficacy maintained in resistant derivatives. Transcriptomic profiling of VL51 cells showed broad gene repression, including MYC, IRF4, NF-κB-related genes, and MCL1, alongside increased expression of HLA class II genes. Moreover, comparison with additional CDK inhibitors revealed a similar transcriptional repression signature, underscoring a conserved CDK-dependent regulatory network. Protein analyses confirmed rapid depletion of MCL1, MYC, RNA polymerase II, and IRF4. Flow cytometry validated increased HLA class II and decreased HLA class I surface expression. Combination studies demonstrated additive to synergistic effects with BTK inhibition (ibrutinib) or dual PI3K/BCL2 inhibition (copanlisib plus venetoclax), independent of baseline drug sensitivity. Mechanistically, these combinations may enhance apoptosis by concurrently suppressing survival signaling and transcriptional addiction. Analysis of patient samples revealed high CDK9 expression, further supporting the biological relevance and therapeutic rationale for targeting CDK9 in this disease. Our findings support the development of CDK9-based combination strategies for relapsed/refractory MZL and other B-cell malignancies, with an additional potential for integration with immunotherapies. Key Points CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, regardless of whether they are resistant to other targeted drugs. PRT2527 boosts the effects of BTK, PI3K, and BCL2 inhibitors and alters immune-related gene expression. Draft of graphical abstract
Year:
2026
Year:
2025
Background BTK and BCL2 represent key therapeutic targets in B-cell lymphomas, including marginal zone lymphoma (MZL). Here, we evaluated the novel BTK degrader BGB-16673, and the second-generation BCL2 inhibitor sonrotoclax in a panel of MZL cell lines, including models with acquired resistance to BTK, BCL2 and PI3K inhibitors, as single agents and in combination. Methods Cytotoxicity, transcriptomic changes, apoptosis, and protein expression were assessed for BGB-16673 alone and in combination with venetoclax, sonrotoclax, bendamustine, selinexor, lenalidomide, and tazemetostat. Results BGB-16673 demonstrated single-agent activity in selected MZL cell lines, inducing BTK degradation and transcriptional repression of BCR signaling and MYC targets. Its transcriptional and phenotypic effects overlapped with those of zanubrutinib but also included specific modulation of oxidative phosphorylation genes. Combination studies revealed that BGB-16673 synergized with other targeted agents, achieving the best results with sonrotoclax, venetoclax, bendamustine, lenalidomide, and rituximab. The mechanism of action of the combination with the BCL2 inhibitors was further evaluated. The combination with sonrotoclax consistently enhanced apoptosis across MZL models, outperforming venetoclax in potency in most cell lines. Sonrotoclax showed over 10-fold higher activity than venetoclax in three MZL lines and demonstrated synergistic interaction with BGB-16673. Mechanistically, the combination leads to BTK degradation and modulation of anti-apoptotic proteins such as BCL2, MCL1, and BCL-XL. Conclusion Our findings underscore the potential of BGB-16673 as a therapeutic agent, both as a monotherapy and in combination regimens, for treating MZL patients. Additionally, the results also identify the second-generation BCL2 inhibitor sonrotoclax as another drug to be explored in the same patient populations.
Year:
2025
B-cell receptor (BCR) signaling is a key therapeutic target in B-cell lymphomas, and Bruton tyrosine kinase inhibitors (BTKi) have demonstrated clinical efficacy in marginal zone lymphoma (MZL). However, the rate of complete remissions is relatively low, and resistance remains a significant clinical challenge, underscoring the need for novel combination strategies. To identify compounds that enhance the activity of BTKi and overcome resistance, we conducted a high-throughput screen of 1,695 compounds using a previously developed MZL model of acquired resistance to BTK and PI3K inhibitors derived from the Karpas1718 cell line. Thirty-three compounds showed single-agent anti-proliferative activity in the nanomolar range, both in the Karpas1718-resistant and parental cells. Based on their clinical potential in combination with BTKi, seven compounds were selected for further validation. The polo-like kinase 1 (PLK1) inhibitor rigosertib emerged as a top candidate, showing strong activity in both parental and BTKi-resistant cell lines. Combination treatment of rigosertib and BTKi zanubrutinib resulted in broad transcriptomic changes, characterized by the downregulation of pathways involved in B-cell activation, proliferation, and BCR signaling. Mechanistically, the combination reduced phosphorylation of key BCR pathway components and inhibited NF-κB nuclear translocation. These findings suggest that PLK1 inhibition can overcome BTKi resistance by further inhibiting BCR signaling through the canonical NF-κB pathway. Therefore, the dual pharmacological inhibition of BTK and PLK1 is a promising therapeutic approach for patients with MZL and warrants further preclinical and clinical investigations.
Year:
2025
Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various approaches, including small molecules, antibodies, and short peptides. Here, we investigated the antitumor effects of the CXCR4 pharmacological inhibition with the synthetic peptides SPX5551 and balixafortide, as single agents and in combination, in various B-cell lymphoma models. Methods: Binding modalities were assessed via molecular docking and simulation. In vitro assays evaluated single-agent and combinatorial effects of CXCR4 antagonists with BTK, PI3K, and conventional therapies across 20 lymphoma cell lines, including models with acquired resistance. Transcriptomic analyses and mechanistic studies elucidated the pathways modulated by combined CXCR4 and BTK inhibition. Results: Structural modeling confirmed similar CXCR4 binding modes for SPX5551 and balixafortide. SPX5551 displayed minimal single-agent activity but restored sensitivity to BTK and PI3K inhibitors in resistant marginal zone lymphoma (MZL) models. Across mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL) models, SPX5551 enhanced the efficacy and/or potency of ibrutinib, copanlisib, rituximab, and R-CHOP. In MCL, co-treatment with SPX5551 and ibrutinib synergistically induced apoptosis, inhibited NF-κB and AKT signaling, and led to broader transcriptomic repression of tumor-promoting pathways compared to either agent alone. Conclusions: Although CXCR4 inhibitors alone show limited cytotoxicity, their combination with standard and targeted therapies significantly enhances anti-lymphoma effects, particularly in drug-resistant settings. These findings provide a strong rationale for clinical evaluation of CXCR4 blockade as a combinatorial strategy in B-cell lymphomas.
Year:
2025
Introducing Bruton’s tyrosine kinase (BTK) inhibitors has significantly improved outcomes for patients with B-cell malignancies and autoimmune disorders. However, resistance, either primary or acquired, remains a major clinical challenge. To better understand the underlying resistance mechanisms to BTK inhibitors, we established an ibrutinib-resistant model from a patient-derived splenic marginal zone lymphoma (MZL) cell line (VL51) through prolonged drug exposure. Resistant cells exhibited a 15-fold increase in ibrutinib’s IC50, along with distinct morphological changes, mitochondrial activation, and cross-resistance to covalent, non-covalent BTK inhibitors and BTK degraders. Integrated transcriptomic, epigenomic, and proteomic analyses identified overexpression and secretion of IL-16 as a key feature of resistance, driven by chromatin remodeling and activation of the FLI1 transcription factor. IL-16 conferred ibrutinib resistance via CD9-mediated activation of the NF-κB and AKT signaling pathways and was found to be elevated in the serum of ibrutinib-refractory CLL patients. Functional studies showed that targeting the IL-16/CD9 axis using neutralizing antibodies or CD9-binding peptides restored sensitivity to BTK inhibitors and R-CHOP chemotherapy in MZL, mantle cell lymphoma, and diffuse large B-cell lymphoma models. These findings reveal a novel, targetable resistance mechanism with potential therapeutic implications for overcoming BTK inhibitor resistance in B-cell lymphomas.
Year:
2025
Multi-omics analyses. Output tables of the moderated t-tests comparing transcriptome, microRNA and methylation profiles of resistant and parental. Output results of Gene Set Enrichment Analysis comparing GEP data of resistant and parental.
Year:
2025
Levels of p-AKT (A, top) and p-ERK (B, bottom) were determined by phospho-flow cytometry upon 1µM of idelalisib. Density plots show the median MFI values of two replicates, negative control (dotted black), parental (grey), resistant (red). (B) Images on the left show the expression of pRELA by immunofluorescence upon 1µM of idelalisib (right) or control (DMSO, left) in parental and resistant (4hr exposure). Boxplot on the right represents the protein quantification from the immunofluorescence experiments. Data derived from two independent experiments. Three representative fields were evaluated from each independent experiment. P-values from Welch Two Sample test performed on mean MFI values.
Year:
2025
Cell viability was evaluated by MTT assay (72h). Karpas1718 parental (A) or resistant (B) were exposed to DMSO (control, black) or decitabine (100nM, red), given concomitantly (continuous lines) or 72 hours before idelalisib (pre DMSO in dashed black or pre decitabine in dashed red). Error bars correspond to standard deviation of the mean. Data derived from two independent experiments. Statistically significant differences were evaluated by moderated t-test comparing each treatment to control (DMSO).
Year:
2025
Ridgeplot on surface levels of ERBB4 by FACS in Karpas1718 resistant cells upon genetic silencing (siRNA) of ERBB2 (yellow), ERBB4 (red) or concomitant ERBB2 and ERBB4 (brown). Silencing control in grey and negative control in black. Data derived from two independent experiments. Statistically significant differences (p
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (42)
Kikkeri N Naresh
Section Head of Pathology & Professor
University of Washington
ANASTASIOS STATHIS
Head of Research Service and Scientific Head Clinical Trial Unit
Istituto Cantonale di Patologia
Javeed Iqbal
Professor, Odeth E. Wall Centennial Professor of Oncology
University of Nebraska Medical Center
Chris Bacon
Clinical Senior Lecturer/Consultant
Newcastle University
Kieron Dunleavy
Director
Georgetown University
Jennifer Brown
Worthington and Margaret Collette Professor of Medicine
Dana-Farber Cancer Institute
Carmelo Carlo‐Stella
IRCCS Humanitas Research Hospital
Davide F. Robbiani
Full Professor
Università del Salento
Seiichi Kato
Professor
Saga University
Francesca Romana Mauro
-
Jan Lukas Bögeholz
University Hospital of Zurich
Karan Kathuria
Stanford University
Lorenzo Leoncini
Docenti di ruolo di Ia fascia
University of Siena
Jan‐Michel Heger
-
Brian Walker
Professor
University of Miami
Giulio Sartori
Università della Svizzera Italiana (USI)
Pedro Farinha
Clinical Professor
The University of British Columbia
Adalgisa Condoluci
Institute of Cancer Research
Catalina Amador
Professor of Pathology
University of Miami Health System
Andrea Cavalli
Group Leader
Institute for Research in Biomedicine
Emanuele Zucca
University of Bern
John Choi
The University of Alabama
Sara Napoli
National Institute of Oncology
Justin Ferdinandus
University Hospital Bonn
Afua Adjeiwaa Mensah
-
Alan Ramsay
King’s College London
Reuben M. Tooze
Professor
University of Leeds
maria ilaria del principe
Associate Prof
UNIVERSITY TOR VERGATA
Federico Simonetta
-
Emanuele Pravatà
Assitant Professor
University “G. d’Annunzio” of Chieti-Pescara
Sarah E. Coupland
Personal Chair
University of Liverpool
Vaskar Saha
The University of Manchester
Vittorio Limongelli
Full Professor
Università del Salento
Alexandar Tzankov
Head Histopathology and Autopsy
University Hospital Basel
Manel Esteller
Group Leader, Cancer Epigenetics Group
Josep Carreras Leukaemia Research Institute
Stefano Luminari
Docenti di ruolo di Ia fascia
University of Modena and Reggio Emilia
qiang pan-hammarstrom
Professor, head of the Immunology Division
Karolinska University Hospital
Ondrej Havranek
Charles University
Bastian von Tresckow
University of Cologne
Ralf Trappe
Head of department
-
Mohammad Shahrokh Esfahani
Assistant Professor
Stanford University
Manuel Castro de Moura
Head of Bioinformatics Unit
Josep Carreras Leukaemia Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.